Biotech Stock News (RXII) (FPRX) (BMY) (ZFGN)

Rxi Pharmaceuticals (NASDAQ:RXII) On October 15, 2015 Rxi Pharmaceuticals announced positive phase 2a results for its RXI-109 compound. The trial, known as RXI-109-1402, was comparing RXI-109 treated scars against scars that were revised by surgery — control group. To test out dosing though Rxi gave one cohort of patients 5 mg/cm of RXI-109 while another … Read more